Galderma Receives NMPA Approval for Relfydess in China

Galderma has received approval from the Chinese NMPA for Relfydess (relabotulinumtoxinA), aimed at temporarily improving moderate-to-severe frown lines in adults. This approval is based on data from a local Phase III clinical trial in China and global studies involving over 2,300 participants. The introduction of Relfydess enhances Galderma's Injectable Aesthetics portfolio in China, complementing its presence in over 35 other regions worldwide.